SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AFFYMETRIX (AFFX)
AFFX 14.010.0%Apr 1 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Paul Weiss who wrote (465)8/25/1997 8:59:00 PM
From: Michael McVey Lusk   of 1728
 
The importance of the Roche news goes beyond the immediate effect on revenues. Although, we can't know the details of the contract, it's clear that a big pharm has made a significant and long-term commitment to AFFX technology, in the belief that EasyAccess will give them a competitive advantage. This will put the other pharms under pressure to match, and we will soon see just how they feel about Genechip. If AFFX really has the right stuff, as I believe it does, we should see a series of additional EasyAccess or similiar contracts signed in the near future.

I agree with you about the suspicious nature of the price moves, although I can't see that it benefits short sellers particuliarly. I too am getting tired of trying to explain mysterious and abrupt 6 point price moves to myself.

Best Regards, MML
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News